Pepdexpepdex
← Back to peptides
Comparison

PT-141 (Bremelanotide) vs Kisspeptin-10

PT-141 vs Kisspeptin for libido: melanocortin pathway vs upstream HPG axis. Two different mechanisms, different use cases.

The verdict

Two completely different routes to the same goal. PT-141 acts on the melanocortin system in the brain, it's an on-demand libido peptide and is FDA-approved (as Vyleesi) for female sexual dysfunction. Kisspeptin works further upstream, kicking off the natural GnRH to LH to testosterone cascade, so it's more about the underlying hormonal axis than a same-day effect. For acute, situational desire, PT-141 is the direct lever. For supporting the hormone cascade itself, Kisspeptin is the one that fits.

012
PT-141 (Bremelanotide)
LibidoEvidence: Strong

PT-141 (FDA-approved as Vyleesi) is the libido peptide. Different mechanism than Viagra, it works on desire, not just blood flow. Used as-needed, not daily. Nausea is the main side effect, especially the first few times.

Onset
95
Documentation
80
Side intensity
100
Popularity
78
032
Kisspeptin-10
LibidoEvidence: Moderate

Kisspeptin sits at the very top of the chain that produces testosterone. When you inject it, your body's own testosterone-making cascade fires off naturally. It's a different lever than PT-141, kisspeptin is upstream hormones, PT-141 is melanocortin pathway.

Onset
95
Documentation
80
Side intensity
64
Popularity
50
Side-by-side
Field
Left
Right
Category
Libido
Libido
Half-life
~2 hours
~4 minutes (kisspeptin-10)
Route
Subcutaneous
Subcutaneous
Schedule
at least 45 min before activity, max 1x per 24h
As needed or 1-2x daily during a short cycle
Cycle length
Use as needed, not daily
Short bursts; not for chronic use
Dose
1.0-1.75 mg sub-q, at least 45 min before activity (FDA Vyleesi label minimum). No more than 1 dose in 24h, no more than 8 doses per month.
25-100 mcg sub-q, 1-2x daily during short courses.
FDA
Approved as Vyleesi (Bremelanotide), 2019, for hypoactive sexual desire disorder in premenopausal women.
Not FDA approved. In clinical investigation for fertility / HPG-axis applications.
WADA
Not listed
Banned (S2)
Natty?
Grey area
Grey area
Prescribed
Yes, Vyleesi prescribed by gynecology, primary care, sexual-medicine providers.
Used in some fertility-medicine research contexts.
Top side effects
Nausea (most common, severe in first uses); Facial flushing; Headache
Generally well tolerated; Mild headache rarely; Brief facial flush

Which one should you pick?

Pick PT-141 (Bremelanotide) if users with situational or low-baseline libido or couples wanting a non-pde5-inhibitor option.

Pick Kisspeptin-10 if users with low lh / suppressed hpg axis post-cycle or fertility-adjacent contexts under medical guidance.

AI Coach · free

Still torn between PT-141 (Bremelanotide) and Kisspeptin-10?

The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.

Ask the Coach: PT-141 (Bremelanotide) vs Kisspeptin-10 →